Azurity Pharmaceuticals Executive and Leadership Team

Ronald Scarboro, the Chief Executive Officer at Azurity Pharmaceuticals, directs the company's overarching strategy and operational execution. Scarboro guides the organization's mission to develop and deliver innovative, high-quality medicines for underserved patients. This leadership involves aligning diverse therapeutic area portfolios and dosage forms with advanced commercial strategies. Scarboro ensures the effective utilization of data and digital tools to enhance market reach and patient engagement. The Chief Executive Officer's focus remains on improving patient outcomes and addressing critical unmet medical needs on a global scale. Ronald Scarboro's strategic vision propels Azurity Pharmaceuticals' commitment to biopharmaceutical advancement and patient care.

Kenneth Bate, the President and Chief Executive Officer at Azurity Pharmaceuticals, spearheads the company's strategic direction and executive leadership. Bate drives the development and delivery of innovative, high-quality medicines targeting underserved patient populations. The President and Chief Executive Officer oversees the integration of diverse therapeutic portfolios and dosage forms, ensuring alignment with advanced commercial strategies. Bate champions the use of data and digital tools to expand market reach and deepen patient engagement. This executive's mandate includes improving patient outcomes and addressing significant unmet medical needs worldwide. Kenneth Bate's leadership ensures Azurity Pharmaceuticals remains at the forefront of biopharmaceutical innovation and patient-centric solutions.

Tom Oneil, the Chief Financial Officer at Azurity Pharmaceuticals, manages the company's financial operations and fiscal strategy. Oneil oversees all aspects of financial planning, budgeting, and reporting, ensuring robust fiscal health. The Chief Financial Officer plays a critical role in resource allocation, supporting the development and delivery of innovative medicines for underserved patients. Oneil evaluates investment opportunities and manages financial risks associated with diverse therapeutic portfolios and advanced commercial strategies. By optimizing financial performance, Tom Oneil directly contributes to enhancing market reach and improving patient outcomes globally. The Chief Financial Officer's expertise is vital for Azurity Pharmaceuticals' sustained growth and its mission to address unmet medical needs.

Jordan Hunter, the Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) at Azurity Pharmaceuticals, orchestrates critical enterprise-wide projects and strategic initiatives. Hunter ensures seamless execution of the company's mission to deliver innovative medicines to underserved patients. The Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) oversees the Project Management Office, driving efficiency and alignment across diverse therapeutic areas and dosage forms. Hunter facilitates the integration of advanced commercial strategies, data, and digital tools to enhance operational reach. Jordan Hunter's role is pivotal in improving patient outcomes and addressing unmet medical needs by ensuring project success and strategic coherence. This leadership ensures Azurity Pharmaceuticals' operational excellence.

Jordan Lilly, the Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) at Azurity Pharmaceuticals, directs the strategic execution of enterprise-level projects and program management. Lilly ensures the effective implementation of Azurity's commitment to developing high-quality medicines for underserved patient populations. The Chief of Staff & Project Management Office Vice President, Enterprise (Epmo) leads the Project Management Office, fostering cross-functional collaboration and optimizing resource deployment across various therapeutic areas. Lilly supports the integration of advanced commercial strategies and digital transformation initiatives to expand market engagement. Jordan Lilly's focus on project success directly supports the company's goal of improving patient outcomes and addressing global unmet medical needs. This leadership ensures strategic initiatives are delivered efficiently.

Elad Sasson, the Deputy Chief Technology Officer at Azurity Pharmaceuticals, drives the technological infrastructure and digital innovation supporting the company's mission. Sasson oversees the implementation of advanced digital tools and data analytics to enhance commercial strategies and operational efficiency. The Deputy Chief Technology Officer plays a key role in ensuring the technological capabilities align with the development and delivery of high-quality medicines for underserved patients. Sasson focuses on leveraging technology to improve patient engagement and outcomes across diverse therapeutic areas. Elad Sasson's technical leadership is instrumental in expanding Azurity Pharmaceuticals' reach and addressing unmet medical needs through cutting-edge solutions. This role ensures the company's technological foundation supports its strategic objectives.

Peter Dyke, the Chief People Officer at Azurity Pharmaceuticals, leads the human capital strategy to support the company's growth and mission. Dyke oversees talent acquisition, development, and retention, ensuring a skilled workforce dedicated to delivering innovative medicines. The Chief People Officer cultivates a culture that fosters collaboration and drives the effective use of advanced commercial strategies and digital tools. Dyke ensures that human resources align with the goal of improving patient outcomes and addressing unmet medical needs globally. Peter Dyke's leadership in people operations is crucial for building a high-performing team committed to Azurity Pharmaceuticals' patient-centric approach. This role ensures the organization has the talent to achieve its strategic objectives.